Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 130000.0
(-1.74%)
KRW 130000.0
(-1.74%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1375.32 Billion KRW | 7.44% |
| 2022 | 1280.09 Billion KRW | 11.03% |
| 2021 | 1152.97 Billion KRW | 9.24% |
| 2020 | 1055.42 Billion KRW | -5.21% |
| 2019 | 1113.42 Billion KRW | 7.95% |
| 2018 | 1031.42 Billion KRW | 7.41% |
| 2017 | 960.3 Billion KRW | 8.64% |
| 2016 | 883.92 Billion KRW | 5.27% |
| 2015 | 839.68 Billion KRW | 14.1% |
| 2014 | 735.88 Billion KRW | 7.82% |
| 2013 | 682.5 Billion KRW | 2.02% |
| 2012 | 669.01 Billion KRW | -5.85% |
| 2011 | 710.54 Billion KRW | 39.32% |
| 2010 | 509.99 Billion KRW | -16.91% |
| 2009 | 613.75 Billion KRW | 11.93% |
| 2008 | 548.32 Billion KRW | 13.21% |
| 2007 | 484.34 Billion KRW | 20.95% |
| 2006 | 400.44 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 335.78 Billion KRW | -7.2% |
| 2024 Q2 | 360.54 Billion KRW | 7.37% |
| 2023 FY | 1375.32 Billion KRW | 7.44% |
| 2023 Q1 | 322.41 Billion KRW | -1.64% |
| 2023 Q4 | 361.82 Billion KRW | 6.14% |
| 2023 Q3 | 340.89 Billion KRW | -2.65% |
| 2023 Q2 | 350.19 Billion KRW | 8.62% |
| 2022 Q3 | 331.89 Billion KRW | 3.05% |
| 2022 Q4 | 327.78 Billion KRW | -1.24% |
| 2022 FY | 1280.09 Billion KRW | 11.03% |
| 2022 Q2 | 322.05 Billion KRW | 7.94% |
| 2022 Q1 | 298.35 Billion KRW | -1.54% |
| 2021 Q3 | 290.64 Billion KRW | 0.33% |
| 2021 Q1 | 269.61 Billion KRW | 0.89% |
| 2021 Q2 | 289.69 Billion KRW | 7.45% |
| 2021 Q4 | 303.01 Billion KRW | 4.26% |
| 2021 FY | 1152.97 Billion KRW | 9.24% |
| 2020 Q4 | 267.24 Billion KRW | -3.46% |
| 2020 Q1 | 257.4 Billion KRW | -10.51% |
| 2020 FY | 1055.42 Billion KRW | -5.21% |
| 2020 Q3 | 276.83 Billion KRW | 9.02% |
| 2020 Q2 | 253.94 Billion KRW | -1.35% |
| 2019 FY | 1113.42 Billion KRW | 7.95% |
| 2019 Q1 | 263.67 Billion KRW | -3.21% |
| 2019 Q3 | 269.43 Billion KRW | -7.94% |
| 2019 Q4 | 287.64 Billion KRW | 6.76% |
| 2019 Q2 | 292.66 Billion KRW | 11.0% |
| 2018 Q3 | 257.98 Billion KRW | -1.39% |
| 2018 FY | 1031.42 Billion KRW | 7.41% |
| 2018 Q1 | 239.42 Billion KRW | 1.08% |
| 2018 Q2 | 261.61 Billion KRW | 9.27% |
| 2018 Q4 | 272.4 Billion KRW | 5.59% |
| 2017 Q1 | 225.93 Billion KRW | -4.36% |
| 2017 FY | 960.3 Billion KRW | 8.64% |
| 2017 Q4 | 236.87 Billion KRW | -6.09% |
| 2017 Q3 | 252.23 Billion KRW | 2.84% |
| 2017 Q2 | 245.26 Billion KRW | 8.56% |
| 2016 FY | 883.92 Billion KRW | 5.27% |
| 2016 Q1 | 211.22 Billion KRW | -1.76% |
| 2016 Q4 | 236.23 Billion KRW | 7.13% |
| 2016 Q3 | 220.51 Billion KRW | 2.12% |
| 2016 Q2 | 215.94 Billion KRW | 2.24% |
| 2015 FY | 839.68 Billion KRW | 14.1% |
| 2015 Q1 | 193.65 Billion KRW | 3.2% |
| 2015 Q2 | 204.17 Billion KRW | 5.43% |
| 2015 Q3 | 226.85 Billion KRW | 11.11% |
| 2015 Q4 | 215 Billion KRW | -5.22% |
| 2014 Q1 | 171.07 Billion KRW | -8.26% |
| 2014 FY | 735.88 Billion KRW | 7.82% |
| 2014 Q3 | 193.48 Billion KRW | 5.34% |
| 2014 Q4 | 187.65 Billion KRW | -3.02% |
| 2014 Q2 | 183.67 Billion KRW | 7.37% |
| 2013 Q2 | 159.76 Billion KRW | -2.21% |
| 2013 Q1 | 163.37 Billion KRW | 13.52% |
| 2013 FY | 682.5 Billion KRW | 2.02% |
| 2013 Q4 | 186.48 Billion KRW | 7.82% |
| 2013 Q3 | 172.95 Billion KRW | 8.26% |
| 2012 FY | 669.01 Billion KRW | -5.85% |
| 2012 Q1 | 172.25 Billion KRW | 0.0% |
| 2012 Q2 | 174.61 Billion KRW | 1.37% |
| 2012 Q3 | 177.25 Billion KRW | 1.51% |
| 2012 Q4 | 143.91 Billion KRW | -18.81% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 710.54 Billion KRW | 39.32% |
| 2011 Q3 | 187.13 Billion KRW | 5.42% |
| 2011 Q2 | 177.52 Billion KRW | 2.65% |
| 2011 Q1 | 172.93 Billion KRW | 0.0% |
| 2010 Q2 | 172.75 Billion KRW | 6.52% |
| 2010 FY | 509.99 Billion KRW | -16.91% |
| 2010 Q3 | 166.73 Billion KRW | -3.49% |
| 2010 Q1 | 162.18 Billion KRW | 5.13% |
| 2009 Q4 | 154.27 Billion KRW | 2.53% |
| 2009 FY | 613.75 Billion KRW | 11.93% |
| 2009 Q3 | 150.47 Billion KRW | 2.5% |
| 2009 Q2 | 146.8 Billion KRW | 0.0% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 FY | 548.32 Billion KRW | 13.21% |
| 2008 Q3 | 137.78 Billion KRW | 4.27% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 Q2 | 132.14 Billion KRW | 0.0% |
| 2008 Q4 | 138.19 Billion KRW | 0.3% |
| 2007 Q2 | 113.31 Billion KRW | 0.0% |
| 2007 FY | 484.34 Billion KRW | 20.95% |
| 2007 Q4 | 126.93 Billion KRW | 5.1% |
| 2007 Q3 | 120.77 Billion KRW | 6.58% |
| 2006 FY | 400.44 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -485.489% |
| Yuhan Corporation | 1858.98 Billion KRW | 26.017% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -902.356% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -115.418% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | -21.495% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -83.738% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -83.738% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | -56.326% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -1452.402% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | -73.06% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -915.957% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -1474.258% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -160.997% |
| Boryung Corporation | 859.62 Billion KRW | -59.992% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -271.171% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 9.187% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -919.443% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -496.948% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -711.081% |
| CKD Bio Corp. | 160.35 Billion KRW | -757.689% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -810.385% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 17.616% |
| Yuhan Corporation | 1858.98 Billion KRW | 26.017% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -586.879% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -902.356% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -512.736% |
| HANDOK Inc. | 522.74 Billion KRW | -163.099% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | -107.134% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 7.751% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -2547.152% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -131.316% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -370.796% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -902.356% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -1662.039% |
| JW Holdings Corporation | 928.07 Billion KRW | -48.192% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -128.932% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | -83.738% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -660.848% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -600.462% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | -89.337% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -586.879% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -393.05% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -280.863% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -992.153% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -271.171% |
| JW Lifescience Corporation | 206.86 Billion KRW | -564.858% |